0001104659-15-044581.txt : 20150610 0001104659-15-044581.hdr.sgml : 20150610 20150610160132 ACCESSION NUMBER: 0001104659-15-044581 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150610 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20150610 DATE AS OF CHANGE: 20150610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Loxo Oncology, Inc. CENTRAL INDEX KEY: 0001581720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462996673 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36562 FILM NUMBER: 15923544 BUSINESS ADDRESS: STREET 1: 1 LANDMARK SQUARE, SUITE 1122 CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-658-4749 MAIL ADDRESS: STREET 1: 1 LANDMARK SQUARE, SUITE 1122 CITY: STAMFORD STATE: CT ZIP: 06901 8-K 1 a15-13893_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report: June 10, 2015

(Date of earliest event reported)

 

LOXO ONCOLOGY, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-36562

 

46-2996673

(Commission File Number)

 

(IRS Employer Identification No.)

 

One Landmark Square, Suite 1122

Stamford, CT

 

06901

(Address of Principal Executive Offices)

 

(Zip Code)

 

(203) 653-3880

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 5.07.             Submission of Matters to a Vote of Security Holders.

 

On June 10, 2015, Loxo Oncology, Inc. (the “Company”) held its 2015 Annual Meeting of Stockholders (“Annual Meeting”) and the following proposals were adopted:

 

1.              Election of two Class I directors, James Barrett and Joshua H. Bilenker, each to serve a three-year term, which will expire at the 2018 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified:

 

Nominees

 

Shares For

 

Shares Withheld

 

Shares Abstaining

 

Broker Non-Votes

James Barrett

 

8,971,541

 

161,063

 

—

 

2,960,945

Joshua H. Bilenker

 

9,090,378

 

42,226

 

—

 

2,960,945

 

2.              Ratification of the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015:

 

Shares For

 

Shares Against

 

Shares Abstaining

 

Broker Non-Votes

11,901,176

 

190,570

 

1,803

 

—

 

3.              Re-approval the Internal Revenue Code Section 162(m) limits of the Company’s 2014 Equity Incentive Plan to preserve the Company’s ability to receive corporate income tax deductions that may become available pursuant to Section 162(m):

 

Shares For

 

Shares Against

 

Shares Abstaining

 

Broker Non-Votes

6,688,901

 

2,443,103

 

600

 

2,960,945

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

Loxo Oncology, Inc.

 

 

 

 

Date: June 10, 2015

By:

/s/ Jennifer Burstein

 

 

Name:

Jennifer Burstein

 

 

Title:

Vice President of Finance and

 

 

 

principal financial officer

 

3